Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company

• AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available 
• Evaxion’s proprietary AI-platforms EDEN and RAVEN will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular immune response to the pathogen
• Collaborative and co-funded project between two companies with strong scientific alignment and complementary skill sets and capabilities
• This collaboration underlines Evaxion’s strategic focus of harnessing the power of AI to identify new targets significantly more efficiently than traditional methods

COPENHAGEN, Denmark, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be a collaboration between Evaxion and an undisclosed leading pharmaceutical company, leveraging unique assets and know-how from both organizations.

To develop an effective vaccine, Evaxion has initiated discovery activities for EVX-B3 using both its EDEN and RAVEN AI platforms to identify protective antigens capable of eliciting both a humoral (antibody) and cellular response to the pathogen. EVX-B3 aims to address a serious global medical issue, targeting a pathogen associated with repeated infections, increasing incidence and often serious medical complications, and for which no vaccines are currently available. The project will be a collaborative and co-funded effort between the two companies.

Evaxion’s Chief Scientific Officer, Birgitte Rønø, states: “We are thrilled to announce our upcoming collaboration, aimed at jointly investigating the capabilities of our AI platforms to design a groundbreaking vaccine targeting this specific pathogen. We strongly believe that this collaboration will further validate the power of AI to benefit global health through the design of unique vaccines against serious medical conditions.”

About EDEN 

EDEN is a proprietary AI platform capable of rapidly identifying those antigens that will trigger a robust and highly protective immune response against virtually any bacterial infectious disease. EDEN is fully AI-driven and designed to identify vaccine candidates faster and cheaper than current state-of-the-art methods. With EDEN, we take a novel approach to vaccine development to combat the rising global issue of antibiotic resistance. For more information, visit our website.